RGEN
REPLIGEN CORP
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$178.88
+0.34%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$183.40
From 52W high−8.06%
Volume501363.00
Market cap$11.43B
P/E (TTM)—
P/S (TTM)14.2x
Div yield—
Key dataNov 4, 2026
Open
$183.40
From 52W high
−8.06%
Volume
501363.00
Market cap
$11.43B
ValuationView details →
P/E (Fwd)
73.5x
EV/EBITDA
89.5x
P/E (TTM)
—
RSI (14)
47.8
MomentumView details →
1D Return
+0.34%
YTD Return
+7.02%
SummaryUpdated Sep 1, 2026
Repligen Corporation (NASDAQ:RGEN) is a leading bioprocessing technology company founded in 1981 and headquartered in Waltham, Massachusetts. The company went public in 1986 and has evolved from its origins as a biotechnology research company into a specialized provider of critical tools and technologies used in the manufacturing of biological drugs. Repligen serves the global biopharmaceutical industry by supplying essential equipment, consumables, and systems that enable the production of life-saving biologics including monoclonal antibodies, vaccines, cell and gene therapies, and other advanced therapeutic modalities.
Similar companies
Latest newsMore news →
REPLIGEN CORP announced that it intends to repurchase its common stock from certain purchasers of its new notes for approximately $120 million, at $188.64 per share.5d agoRepligen announced agreements to issue $1.0 billion of 0.25% convertible senior notes due 2031, including $541.4 million in exchange for $456.8 million of its 2028 notes and $458.6 million for cash.5d agoREPLIGEN CORP reported third-quarter 2026 revenue of $209.3 million, up 11% year over year, and a net loss of $38.4 million, and provided full-year 2026 guidance.7d ago